Relationship of prostate biopsy positive results and preoperative examination in prostate specific antigen gray area patients
WANG Mei-cai1 ZHOU Rong-sheng2 ZHOU Xiang-ju2 PANG Kun2▲ HAN Cong-hui2▲
1.Department of Urology,Central Hospital of Shuyang County in Jiangsu Province,Shuyang 223600,China;
2.Department of Urology,Xuzhou City Central Hospital Affiliated to Southeast University in Jiangsu Province,Xuzhou 221000,China.
Abstract:ObjectiveTo investigate correlation of prostate biopsy positive results and preoperative examination in prostate specific antigen (PSA)Gray area patients.Methods495 patients who underwent prostatic biopsy in the PSA gray area from March 2011 to March 2016 in Department of Urology of Central Hospital of Shuyang County and Xuzhou City Central Hospital were retrospectively studied and divided into two groups of prostatic biopsy positive group(n=150) and prostatic biopsy negative group (n=345)according to the results of prostatic biopsy.Age,smoking or not,whether hypertension,whether diabetes,MRI nodules,digital rectal examination (DRE)nodules,PSA,free PSA (FPSA),PSA density (PSAD),prostate volume between two groups were compared,and correlation of puncture positive result and preoperative examination was analyzed.ResultsThere were no significant differences between two groups in age,smoking or not, whether hypertension,whether diabetes,and FPSA,prostate volume between two groups(P=0.1078,0.6375,0.0517,0.4811, 0.1363,0.2915;all P>0.05);There were statistically significant difference in MRI nodules,DRE nodules,PSA,PSAD(all P<0.01).Pearson correlation analysis results showed that MRI nodules,DRE nodules,PSA,PSAD had positive correlation with transrectal prostate biopsy positive (r=0.236,0.536,0.331,0.536;all P<0.05).Conclusion Positive rate of puncture is higher in patients of PSA gray area with higher PSA,higher PASD,MRI or DRE found nodules;age,smoking,hypertension,diabetes,FPSA have no relationship with puncture result.
Moul JW.Comparison of DRE and PSA in the detection of prostate cancer[J].J Urol,2017,197(2S):S208-S209.
[10]
Zhang M,Chen L,Yuan Z,et al.Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers[J].Discov Med,2016,22(122):281-295.
[11]
Cochetti G,Poli G,Guelfi G,et al.Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia:evaluation of potential diagnostic and prognostic role[J].Onco Targets Ther,2016,13(9):7545-7553.
[12]
Fu AZ,Tsai HT,Haque R,et al.Mortality and androgendeprivation therapy as salvage treatment for biochemical recurrence after primary therapy for clinically localized prostate cancer[J].J Urol,2016.[Epub ahead of print].
[13]
Turner RM,Yabes JG,Woldemichael E,et al.Prognostic implications of immediate PSA response to early salvage radiotherapy[J].Can J Urol,2016,23(6):8568-8575.
[14]
Elabbady A,Hashad MM,Kotb AF,et al.Studying the effect of type 2 diabetes mellitus on prostate-related parameters:a prospective single institutional study[J].Prostate Int,2016,4(4):156-159.
[15]
Cabarkapa S,Perera M,McGrath S,et al.Prostate cancer screening with prostate-specific antigen:a guide to the guidelines[J].Prostate Int,2016,4(4):125-129.